Merck: Proscar Does What It's Designed To Do

Your article about Proscar, Merck's new drug for symptomatic benign prostate enlargement ("Critics are ganging up on Merck's new wonder drug," Top of the News, July 20), does not fully reflect Merck's knowledge about the drug's efficiency and safety. In fact, several questions raised by the article are answered in the prescribing information for doctors, which was not widely available at the time of publication.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.